• 1
    Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P, Selz F, Hue C, Certain S, Casanova JL, Bousso P, Deist FL, Fischer A. 2000. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288: 669672.
  • 2
    Hyde SC, Southern KW, Gileadi U, Fitzjohn EM, Mofford KA, Waddell BE, Gooi HC, Goddard CA, Hannavy K, Smyth SE, Egan JJ, Sorgi FL, Huang L, Cuthbert AW, Evans MJ, Colledge WH, Higgins CF, Webb AK, Gill DR. 2000. Repeat administration of DNA/liposomes to the nasal epithelium of patients with cystic fibrosis. Gene Ther 7: 11561165.
  • 3
    Nabel GJ, Nabel EG, Yang ZY, Fox BA, Plautz GE, Gao X, Huang L, Shu S, Gordon D, Chang AE. 1993. Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci USA 90: 1130711311.
  • 4
    Restifo NP, Ying H, Hwang L, Leitner WW. 2000. The promise of nucleic acid vaccines. Gene Ther 7: 8992.
  • 5
    Dewey RA, Morrissey G, Cowsill CM, Stone D, Bolognani F, Dodd NJ, Southgate TD, Klatzmann D, Lassmann H, Castro MG, Lowenstein PR. 1999. Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: Implications for clinical trials. Nat Med 5: 12561263.
  • 6
    Fox JL. 2000. Gene-therapy death prompts broad civil lawsuit. Nat Biotechnol 18: 1136.
  • 7
    Akinc A, Zumbuehl A, Goldberg M, Leshchiner ES, Busini V, Hossain N, Bacallado SA, Nguyen DN, Fuller J, Alvarez R, Borodovsky A, Borland T, Constien R, de Fougerolles A, Dorkin JR, Narayanannair Jayaprakash K, Jayaraman M, John M, Koteliansky V, Manoharan M, Nechev L, Qin J, Racie T, Raitcheva D, Rajeev KG, Sah DW, Soutschek J, Toudjarska I, Vornlocher HP, Zimmermann TS, Langer R, Anderson DG. 2008. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol 26: 561569.
  • 8
    Akinc A, Goldberg M, Qin J, Dorkin JR, Gamba-Vitalo C, Maier M, Jayaprakash KN, Jayaraman M, Rajeev KG, Manoharan M, Koteliansky V, Rohl I, Leshchiner ES, Langer R, Anderson DG. 2009. Development of lipidoid-siRNA formulations for systemic delivery to the liver. Mol Ther 17: 872879.
  • 9
    2009. Gene therapy clinical trials world wide. J Gene Med
  • 10
    Garber K. 2006. China approves world's first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst 98: 298300.
  • 11
    Gordon EM, Hall FL. 2010. Rexin-G, a targeted genetic medicine for cancer. Expert Opin Biol Ther 10: 819832.
  • 12
    Rainov NG. 2000. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 11: 23892401.
  • 13
    Kirn D. 2001. Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): Results of phase I and II trials. Expert Opin Biol Ther 1: 525538.
  • 14
    Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Veres G, Schmidt M, Kutschera I, Vidaud M, Abel U, Dal-Cortivo L, Caccavelli L, Mahlaoui N, Kiermer V, Mittelstaedt D, Bellesme C, Lahlou N, Lefrere F, Blanche S, Audit M, Payen E, Leboulch P, l'Homme B, Bougneres P, Von Kalle C, Fischer A, Cavazzana-Calvo M, Aubourg P. 2009. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326: 818823.
  • 15
    Wagner E. 2008. Converging paths of viral and non-viral vector engineering. Mol Ther 16: 12.
  • 16
    Fraley R, Subramani S, Berg P, Papahadjopoulos D. 1980. Introduction of liposome-encapsulated SV40 DNA into cells. J Biol Chem 255: 1043110435.
  • 17
    Fraley R, Straubinger RM, Rule G, Springer EL, Papahadjopoulos D. 1981. Liposome-mediated delivery of deoxyribonucleic acid to cells: Enhanced efficiency of delivery related to lipid composition and incubation conditions. Biochemistry 20: 69786987.
  • 18
    Straubinger RM, Papahadjopoulos D. 1983. Liposomes as carriers for intracellular delivery of nucleic acids. Methods Enzymol 101: 512527.
  • 19
    Felgner PL, Gadek TR, Holm M, Roman R, Chan HW, Wenz M, Northrop JP, Ringold GM, Danielsen M. 1987. Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA 84: 74137417.
  • 20
    Fraley RT, Dellaporta SL, Papahadjopoulos D. 1982. Liposome-mediated delivery of tobacco mosaic virus RNA into tobacco protoplasts: A sensitive assay for monitoring liposome-protoplast interactions. Proc Natl Acad Sci USA 79: 18591863.
  • 21
    Malone RW, Felgner PL, Verma IM. 1989. Cationic liposome-mediated RNA transfection. Proc Natl Acad Sci USA 86: 60776081.
  • 22
    Patel MM, Anchordoquy TJ. 2006. Ability of spermine to differentiate between DNA sequences—Preferential stabilization of A-tracts. Biophys Chem 122: 515.
  • 23
    Hansma HG, Golan R, Hsieh W, Lollo CP, Mullen-Ley P, Kwoh D. 1998. DNA condensation for gene therapy as monitored by atomic force microscopy. Nucleic Acids Res 26: 24812487.
  • 24
    Golan R, Pietrasanta LI, Hsieh W, Hansma HG. 1999. DNA toroids: Stages in condensation. Biochemistry 38: 1406914076.
  • 25
    Patel MM, Anchordoquy TJ. 2005. Contribution of hydrophobicity to thermodynamics of ligand-DNA binding and DNA collapse. Biophys J 88: 20892103.
  • 26
    Bloomfield VA. 1991. Condensation of DNA by multivalent cations: Considerations on mechanism. Biopolymers 31: 14711481.
  • 27
    Perales JC, Ferkol T, Molas M, Hanson RW. 1994. An evaluation of receptor-mediated gene transfer using synthetic DNA-ligand complexes. Eur J Biochem 226: 255266.
  • 28
    Perales JC, Ferkol T, Beegen H, Ratnoff OD, Hanson RW. 1994. Gene transfer in vivo: Sustained expression and regulation of genes introduced into the liver by receptor-targeted uptake. Proc Natl Acad Sci USA 91: 40864090.
  • 29
    Patel MM, Anchordoquy TJ. 2010. Significant differences in binding stoichiometry of spermine to RNA than to DNA oligonucleotides. in preparation
  • 30
    Bouxsein NF, McAllister CS, Ewert KK, Samuel CE, Safinya CR. 2007. Structure and gene silencing activities of monovalent and pentavalent cationic lipid vectors complexed with siRNA. Biochemistry 46: 47854792.
  • 31
    Lu JJ, Langer R, Chen J. 2009. A novel mechanism is involved in cationic lipid-mediated functional siRNA delivery. Mol Pharm 6: 763771.
  • 32
    Spagnou S, Miller AD, Keller M. 2004. Lipidic carriers of siRNA: Differences in the formulation, cellular uptake, and delivery with plasmid DNA. Biochemistry 43: 1334813356.
  • 33
    Malek A, Czubayko F, Aigner A. 2008. PEG grafting of polyethylenimine (PEI) exerts different effects on DNA transfection and siRNA-induced gene targeting efficacy. J Drug Target 16: 124139.
  • 34
    Zelphati O, Uyechi LS, Barron LG, Szoka FC, Jr. 1998. Effect of serum components on the physico-chemical properties of cationic lipid/oligonucleotide complexes and on their interactions with cells. Biochim Biophys Acta 1390: 119133.
  • 35
    Thierry AR, Rabinovich P, Peng B, Mahan LC, Bryant JL, Gallo RC. 1997. Characterization of liposome-mediated gene delivery: Expression, stability and pharmacokinetics of plasmid DNA. Gene Ther 4: 226237.
  • 36
    Yang JP, Huang L. 1997. Overcoming the inhibitory effect of serum on lipofection by increasing the charge ratio of cationic liposome to DNA. Gene Ther 4: 950960.
  • 37
    Yang JP, Huang L. 1998. Time-dependent maturation of cationic liposome-DNA complex for serum resistance. Gene Ther 5: 380387.
  • 38
    Zhang Y, Anchordoquy TJ. 2004. The role of lipid charge density in the serum stability of cationic lipid/DNA complexes. Biochim Biophys Acta 1663: 143157.
  • 39
    Ogris M, Brunner S, Schuller S, Kircheis R, Wagner E. 1999. PEGylated DNA/transferrin-PEI complexes: Reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery. Gene Ther 6: 595605.
  • 40
    Plank C, Mechtler K, Szoka FC, Jr., Wagner E. 1996. Activation of the complement system by synthetic DNA complexes: A potential barrier for intravenous gene delivery. Hum Gene Ther 7: 14371446.
  • 41
    Crook K, Stevenson BJ, Dubouchet M, Porteous DJ. 1998. Inclusion of cholesterol in DOTAP transfection complexes increases the delivery of DNA to cells in vitro in the presence of serum. Gene Ther 5: 137143.
  • 42
    Li S, Tseng WC, Stolz DB, Wu SP, Watkins SC, Huang L. 1999. Dynamic changes in the characteristics of cationic lipidic vectors after exposure to mouse serum: Implications for intravenous lipofection. Gene Ther 6: 585594.
  • 43
    Wheeler JJ, Palmer L, Ossanlou M, MacLachlan I, Graham RW, Zhang YP, Hope MJ, Scherrer P, Cullis PR. 1999. Stabilized plasmid-lipid particles: Construction and characterization. Gene Ther 6: 271281.
  • 44
    Wolff JA, Dowty ME, Jiao S, Repetto G, Berg RK, Ludtke JJ, Williams P, Slautterback DB. 1992. Expression of naked plasmids by cultured myotubes and entry of plasmids into T tubules and caveolae of mammalian skeletal muscle. J Cell Sci 103: 12491259.
  • 45
    Hafez IM, Maurer N, Cullis PR. 2001. On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids. Gene Ther 8: 11881196.
  • 46
    Xu Y, Szoka FC, Jr. 1996. Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. Biochemistry 35: 56165623.
  • 47
    Juliano R, Bauman J, Kang H, Ming X. 2009. Biological barriers to therapy with antisense and siRNA oligonucleotides. Mol Pharm 6: 686695.
  • 48
    Sakurai F, Nishioka T, Saito H, Baba T, Okuda A, Matsumoto O, Taga T, Yamashita F, Takakura Y, Hashida M. 2001. Interaction between DNA-cationic liposome complexes and erythrocytes is an important factor in systemic gene transfer via the intravenous route in mice: The role of the neutral helper lipid. Gene Ther 8: 677686.
  • 49
    Smyth Templeton N. 2003. Cationic liposomes as in vivo delivery vehicles. Curr Med Chem 10: 12791287.
  • 50
    Torchilin VP, Omelyanenko VG, Papisov MI, Bogdanov AA, Jr., Trubetskoy VS, Herron JN, Gentry CA. 1994. Poly(ethylene glycol) on the liposome surface: On the mechanism of polymer-coated liposome longevity. Biochim Biophys Acta 1195: 1120.
  • 51
    Torchilin VP, Shtilman MI, Trubetskoy VS, Whiteman K, Milstein AM, Torchilin VP, Omelyanenko VG, Papisov MI, Bogdanov AA, Jr., Trubetskoy VS, Herron JN, Gentry CA. 1994. Amphiphilic vinyl polymers effectively prolong liposome circulation time in vivo. Biochim Biophys Acta 1195: 181184.
  • 52
    Harvie P, Wong FM, Bally MB. 2000. Use of poly(ethylene glycol)-lipid conjugates to regulate the surface attributes and transfection activity of lipid-DNA particles. J Pharm Sci 89: 652663.
  • 53
    Gabizon A, Papahadjopoulos D. 1988. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci USA 85: 69496953.
  • 54
    Chiu GN, Bally MB, Mayer LD. 2001. Selective protein interactions with phosphatidylserine containing liposomes alter the steric stabilization properties of poly(ethylene glycol). Biochim Biophys Acta 1510: 5669.
  • 55
    Li WM, Mayer LD, Bally MB. 2002. Prevention of antibody-mediated elimination of ligand-targeted liposomes by using poly(ethylene glycol)-modified lipids. J Pharmacol Exp Ther 300: 976983.
  • 56
    Allen C, Dos Santos N, Gallagher R, Chiu GN, Shu Y, Li WM, Johnstone SA, Janoff AS, Mayer LD, Webb MS, Bally MB. 2002. Controlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly(ethylene glycol). Biosci Rep 22: 225250.
  • 57
    Dos Santos N, Allen C, Doppen AM, Anantha M, Cox KA, Gallagher RC, Karlsson G, Edwards K, Kenner G, Samuels L, Webb MS, Bally MB. 2007. Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: Relating plasma circulation lifetimes to protein binding. Biochim Biophys Acta 1768: 13671377.
  • 58
    Moghimi SM, Muir IS, Illum L, Davis SS, Kolb-Bachofen V. 1993. Coating particles with a block co-polymer (poloxamine-908) suppresses opsonization but permits the activity of dysopsonins in the serum. Biochim Biophys Acta 1179: 157165.
  • 59
    Moghimi SM, Patel HM. 1989. Serum opsonins and phagocytosis of saturated and unsaturated phospholipid liposomes. Biochim Biophys Acta 984: 384387.
  • 60
    Johnstone SA, Masin D, Mayer L, Bally MB. 2001. Surface-associated serum proteins inhibit the uptake of phosphatidylserine and poly(ethylene glycol) liposomes by mouse macrophages. Biochim Biophys Acta 1513: 2537.
  • 61
    Hyvonen Z, Ronkko S, Toppinen MR, Jaaskelainen I, Plotniece A, Urtti A. 2004. Dioleoyl phosphatidylethanolamine and PEG-lipid conjugates modify DNA delivery mediated by 1,4-dihydropyridine amphiphiles. J Control Release 99: 177190.
  • 62
    Monck MA, Mori A, Lee D, Tam P, Wheeler JJ, Cullis PR, Scherrer P. 2000. Stabilized plasmid-lipid particles: Pharmacokinetics and plasmid delivery to distal tumors following intravenous injection. J Drug Target 7: 439452.
  • 63
    Shi F, Wasungu L, Nomden A, Stuart MC, Polushkin E, Engberts JB, Hoekstra D. 2002. Interference of poly(ethylene glycol)-lipid analogues with cationic-lipid-mediated delivery of oligonucleotides; role of lipid exchangeability and non-lamellar transitions. Biochem J 366: 333341.
  • 64
    Tam P, Monck M, Lee D, Ludkovski O, Leng EC, Clow K, Stark H, Scherrer P, Graham RW, Cullis PR. 2000. Stabilized plasmid-lipid particles for systemic gene therapy. Gene Ther 7: 18671874.
  • 65
    Armstrong TK, Girouard LG, Anchordoquy TJ. 2002. Effects of PEGylation on the preservation of cationic lipid/DNA complexes during freeze-thawing and lyophilization. J Pharm Sci 91: 25492558.
  • 66
    Deshpande MC, Davies MC, Garnett MC, Williams PM, Armitage D, Bailey L, Vamvakaki M, Armes SP, Stolnik S. 2004. The effect of poly(ethylene glycol) molecular architecture on cellular interaction and uptake of DNA complexes. J Control Release 97: 143156.
  • 67
    Li SD, Chono S, Huang L. 2008. Efficient gene silencing in metastatic tumor by siRNA formulated in surface-modified nanoparticles. J Control Release 126: 7784.
  • 68
    Remaut K, Lucas B, Braeckmans K, Demeester J, De Smedt SC. 2007. Pegylation of liposomes favours the endosomal degradation of the delivered phosphodiester oligonucleotides. J Control Release 117: 256266.
  • 69
    Adlakha-Hutcheon G, Bally MB, Shew CR, Madden TD. 1999. Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity. Nat Biotechnol 17: 775779.
  • 70
    Li W, Huang Z, MacKay JA, Grube S, Szoka FC, Jr. 2005. Low-pH-sensitive poly(ethylene glycol; PEG)-stabilized plasmid nanolipoparticles: Effects of PEG chain length, lipid composition and assembly conditions on gene delivery. J Gene Med 7: 6779.
  • 71
    Shin J, Shum P, Thompson DH. 2003. Acid-triggered release via dePEGylation of DOPE liposomes containing acid-labile vinyl ether PEG-lipids. J Control Release 91: 187200.
  • 72
    Hatakeyama H, Akita H, Kogure K, Oishi M, Nagasaki Y, Kihira Y, Ueno M, Kobayashi H, Kikuchi H, Harashima H. 2007. Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid. Gene Ther 14: 6877.
  • 73
    Webb MS, Saxon D, Wong FM, Lim HJ, Wang Z, Bally MB, Choi LS, Cullis PR, Mayer LD. 1998. Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): Effects on the pharmacokinetics of liposomal vincristine. Biochim Biophys Acta 1372: 272282.
  • 74
    Schuch G. 2005. EndoTAG-1. MediGene. Curr Opin Investig Drugs 6: 12591265.
  • 75
    Eichhorn ME, Luedemann S, Strieth S, Papyan A, Ruhstorfer H, Haas H, Michaelis U, Sauer B, Teifel M, Enders G, Brix G, Jauch KW, Bruns CJ, Dellian M. 2007. Cationic lipid complexed camptothecin (EndoTAG-2) improves antitumoral efficacy by tumor vascular targeting. Cancer Biol Ther 6: 920929.
  • 76
    Eichhorn ME, Ischenko I, Luedemann S, Strieth S, Papyan A, Werner A, Bohnenkamp H, Guenzi E, Preissler G, Michaelis U, Jauch KW, Bruns CJ, Dellian M. 2010. Vascular targeting by EndoTAG-1 enhances therapeutic efficacy of conventional chemotherapy in lung and pancreatic cancer. Int J Cancer 126: 12351245.
  • 77
    Allison SD. 2008. Effect of structural relaxation on the preparation and drug release behavior of poly(lactic-co-glycolic)acid microparticle drug delivery systems. J Pharm Sci 97: 20222035.
  • 78
    Prabha S, Zhou WZ, Panyam J, Labhasetwar V. 2002. Size-dependency of nanoparticle-mediated gene transfection: Studies with fractionated nanoparticles. Int J Pharm 244: 105115.
  • 79
    Lerman LS. 1971. A transition to a compact form of DNA in polymer solutions. Proc Natl Acad Sci USA 68: 18861890.
  • 80
    Evdokimov YM, Platonov AL, Tikhonenko AS, Varshavsky YM. 1972. A compact form of double-stranded DNA in solution. FEBS Lett 23: 180184.
  • 81
    Madden TD, Harrigan PR, Tai LC, Bally MB, Mayer LD, Redelmeier TE, Loughrey HC, Tilcock CP, Reinish LW, Cullis PR. 1990. The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: A survey. Chem Phys Lipids 53: 3746.
  • 82
    Fenske DB, MacLachlan I, Cullis PR. 2002. Stabilized plasmid-lipid particles: A systemic gene therapy vector. Methods Enzymol 346: 3671.
  • 83
    Fenske DB, MacLachlan I, Cullis PR. 2001. Long-circulating vectors for the systemic delivery of genes. Curr Opin Mol Ther 3: 153158.
  • 84
    Maurer N, Wong KF, Stark H, Louie L, McIntosh D, Wong T, Scherrer P, Semple SC, Cullis PR. 2001. Spontaneous entrapment of polynucleotides upon electrostatic interaction with ethanol-destabilized cationic liposomes. Biophys J 80: 23102326.
  • 85
    Semple SC, Klimuk SK, Harasym TO, Dos Santos N, Ansell SM, Wong KF, Maurer N, Stark H, Cullis PR, Hope MJ, Scherrer P. 2001. Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: Formation of novel small multilamellar vesicle structures. Biochim Biophys Acta 1510: 152166.
  • 86
    Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN, Harborth J, Heyes JA, Jeffs LB, John M, Judge AD, Lam K, McClintock K, Nechev LV, Palmer LR, Racie T, Rohl I, Seiffert S, Shanmugam S, Sood V, Soutschek J, Toudjarska I, Wheat AJ, Yaworski E, Zedalis W, Koteliansky V, Manoharan M, Vornlocher HP, MacLachlan I. 2006. RNAi-mediated gene silencing in non-human primates. Nature 441: 111114.
  • 87
    Frank-Kamenetsky M, Grefhorst A, Anderson NN, Racie TS, Bramlage B, Akinc A, Butler D, Charisse K, Dorkin R, Fan Y, Gamba-Vitalo C, Hadwiger P, Jayaraman M, John M, Jayaprakash KN, Maier M, Nechev L, Rajeev KG, Read T, Rohl I, Soutschek J, Tan P, Wong J, Wang G, Zimmermann T, de Fougerolles A, Vornlocher HP, Langer R, Anderson DG, Manoharan M, Koteliansky V, Horton JD, Fitzgerald K. 2008. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci USA 105: 1191511920.
  • 88
    Heyes J, Palmer L, Chan K, Giesbrecht C, Jeffs L, MacLachlan I. 2007. Lipid encapsulation enables the effective systemic delivery of polyplex plasmid DNA. Mol Ther 15: 713720.
  • 89
    Jeffs LB, Palmer LR, Ambegia EG, Giesbrecht C, Ewanick S, MacLachlan I. 2005. A scalable, extrusion-free method for efficient liposomal encapsulation of plasmid DNA. Pharm Res 22: 362372.
  • 90
    Bailey AL, Sullivan SM. 2000. Efficient encapsulation of DNA plasmids in small neutral liposomes induced by ethanol and calcium. Biochim Biophys Acta 1468: 239252.
  • 91
    Gao K, Huang L. 2009. Nonviral methods for siRNA delivery. Mol Pharm 6: 651658.
  • 92
    Fernandez CAK, Baumhover N, Rice K. 2009. Gene delivery using polyacridne-PEG-peptides. Annual Meeting of American Association of Pharmaceutical Scientists poster T3050.
  • 93
    Zhang Y, Bradshaw-Pierce EL, Delille A, Gustafson DL, Anchordoquy TJ. 2008. In vivo comparative study of lipid/DNA complexes with different in vitro serum stability: Effects on biodistribution and tumor accumulation. J Pharm Sci 97: 237250.
  • 94
    Woodle MC, Scaria P, Ganesh S, Subramanian K, Titmas R, Cheng C, Yang J, Pan Y, Weng K, Gu C, Torkelson S. 2001. Sterically stabilized polyplex: Ligand-mediated activity. J Control Release 74: 309311.
  • 95
    Ogris M, Walker G, Blessing T, Kircheis R, Wolschek M, Wagner E. 2003. Tumor-targeted gene therapy: Strategies for the preparation of ligand-polyethylene glycol-polyethylenimine/DNA complexes. J Control Release 91: 173181.
  • 96
    Verbaan FJ, Oussoren C, Snel CJ, Crommelin DJ, Hennink WE, Storm G. 2004. Steric stabilization of poly(2-(dimethylamino)ethyl methacrylate)-based polyplexes mediates prolonged circulation and tumor targeting in mice. J Gene Med 6: 6475.
  • 97
    Xu L, Anchordoquy TJ. 2008. Cholesterol domains in cationic lipid/DNA complexes improve transfection. Biochim Biophys Acta 1778: 21772181.
  • 98
    Xu L, Anchordoquy TJ. 2010. Effect of cholesterol nanodomains on the targeting of lipid-based gene delivery in cultured cells. Mol Pharm In press.
  • 99
    Xu L, Huang CC, Huang W, Tang WH, Rait A, Yin YZ, Cruz I, Xiang LM, Pirollo KF, Chang EH. 2002. Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. Mol Cancer Ther 1: 337346.
  • 100
    Bruckheimer E, Harvie P, Orthel J, Dutzar B, Furstoss K, Mebel E, Anklesaria P, Paul R. 2004. In vivo efficacy of folate-targeted lipid-protamine-DNA (LPD-PEG-Folate) complexes in an immunocompetent syngeneic model for breast adenocarcinoma. Cancer Gene Ther 11: 128134.
  • 101
    Harvie P, Dutzar B, Galbraith T, Cudmore S, O'Mahony D, Anklesaria P, Paul R. 2003. Targeting of lipid-protamine-DNA (LPD) lipopolyplexes using RGD motifs. J Liposome Res 13: 231247.
  • 102
    Mamot C, Drummond DC, Noble CO, Kallab V, Guo Z, Hong K, Kirpotin DB, Park JW. 2005. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res 65: 1163111638.
  • 103
    Davis ME. 2009. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: From concept to clinic. Mol Pharm 6: 659668.
  • 104
    Fernandez CA, Rice KG. 2009. Engineered nanoscaled polyplex gene delivery systems. Mol Pharm 6: 12771289.
  • 105
    Lukyanov AN, Gao Z, Torchilin VP. 2003. Micelles from polyethylene glycol/phosphatidylethanolamine conjugates for tumor drug delivery. J Control Release 91: 97102.
  • 106
    Torchilin V. 2004. Polymeric immunomicelles: Carriers of choice for targeted delivery of water-insoluble pharmaceuticals. Drug Deliv Technol 4.
  • 107
    Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD, Ribas A. 2010. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464: 10671070.
  • 108
    Hattori Y, Maitani Y. 2005. Folate-linked lipid-based nanoparticle for targeted gene delivery. Curr Drug Deliv 2: 243252.
  • 109
    Ward CM, Pechar M, Oupicky D, Ulbrich K, Seymour LW. 2002. Modification of pLL/DNA complexes with a multivalent hydrophilic polymer permits folate-mediated targeting in vitro and prolonged plasma circulation in vivo. J Gene Med 4: 536547.
  • 110
    Leamon CP, Cooper SR, Hardee GE. 2003. Folate-liposome-mediated antisense oligodeoxynucleotide targeting to cancer cells: Evaluation in vitro and in vivo. Bioconjug Chem 14: 738747.
  • 111
    Knoll D, Hermans J. 1983. Polymer-protein interactions. Comparison of experiment and excluded volume theory. J Biol Chem 258: 57105715.
  • 112
    Schaffer DV, Lauffenburger DA. 1998. Optimization of cell surface binding enhances efficiency and specificity of molecular conjugate gene delivery. J Biol Chem 273: 2800428009.
  • 113
    Handl HL, Sankaranarayanan R, Josan JS, Vagner J, Mash EA, Gillies RJ, Hruby VJ. 2007. Synthesis and evaluation of bivalent NDP-alpha-MSH(7) peptide ligands for binding to the human melanocortin receptor 4 (hMC4R). Bioconjug Chem 18: 11011109.
  • 114
    Sebestyen MG, Budker VG, Budker T, Subbotin VM, Zhang G, Monahan SD, Lewis DL, Wong SC, Hagstrom JE, Wolff JA. 2006. Mechanism of plasmid delivery by hydrodynamic tail vein injection. I. Hepatocyte uptake of various molecules. J Gene Med 8: 852873.
  • 115
    Lewis DL, Wolff JA. 2007. Systemic siRNA delivery via hydrodynamic intravascular injection. Adv Drug Deliv Rev 59: 115123.
  • 116
    Anchordoquy TJ, Armstrong TK, Molina MC. 2005. Low molecular weight dextrans stabilize nonviral vectors during lyophilization at low osmolalities: Concentrating suspensions by rehydration to reduced volumes. J Pharm Sci 94: 12261236.
  • 117
    Zillies JC, Zwiorek K, Hoffmann F, Vollmar A, Anchordoquy TJ, Winter G, Coester C. 2008. Formulation development of freeze-dried oligonucleotide-loaded gelatin nanoparticles. Eur J Pharm Biopharm 70: 514521.
  • 118
    Patel HM. 1992. Serum opsonins and liposomes: Their interaction and opsonophagocytosis. Crit Rev Ther Drug Carrier Syst 9: 3990.
  • 119
    Cullis PR, Chonn A, Semple SC. 1998. Interactions of liposomes and lipid-based carrier systems with blood proteins: Relation to clearance behaviour in vivo. Adv Drug Deliv Rev 32: 317.
  • 120
    Kamps JA, Scherphof GL. 1998. Receptor versus non-receptor mediated clearance of liposomes. Adv Drug Deliv Rev 32: 8197.
  • 121
    Ishida T, Harashima H, Kiwada H. 2001. Interactions of liposomes with cells in vitro and in vivo: Opsonins and receptors. Curr Drug Metab 2: 397409.
  • 122
    Geng Y, Discher DE. 2005. Hydrolytic degradation of poly(ethylene oxide)-block-polycaprolactone worm micelles. J Am Chem Soc 127: 1278012781.
  • 123
    Zhang JS, Liu F, Huang L. 2005. Implications of pharmacokinetic behavior of lipoplex for its inflammatory toxicity. Adv Drug Deliv Rev 57: 689698.
  • 124
    Li SD, Huang L. 2008. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm 5: 496504.
  • 125
    Liu D, Mori A, Huang L. 1992. Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM1-containing liposomes. Biochim Biophys Acta 1104: 95101.
  • 126
    Li SD, Huang L. 2008. Targeted delivery of siRNA by nonviral vectors: Lessons learned from recent advances. Curr Opin Investig Drugs 9: 13171323.
  • 127
    Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, Marks JD, Benz CC, Park JW. 2006. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 66: 67326740.
  • 128
    Perrault SD, Walkey C, Jennings T, Fischer HC, Chan WC. 2009. Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett 9: 19091915.
  • 129
    Lundqvist M, Stigler J, Elia G, Lynch I, Cedervall T, Dawson KA. 2008. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc Natl Acad Sci USA 105: 1426514270.
  • 130
    Li SD, Huang L. 2007. Non-viral is superior to viral gene delivery. J Control Release 123: 181183.
  • 131
    Li S, Wu SP, Whitmore M, Loeffert EJ, Wang L, Watkins SC, Pitt BR, Huang L. 1999. Effect of immune response on gene transfer to the lung via systemic administration of cationic lipidic vectors. Am J Physiol 276: L796L804.
  • 132
    Whitmore M, Li S, Huang L. 1999. LPD lipopolyplex initiates a potent cytokine response and inhibits tumor growth. Gene Ther 6: 18671875.
  • 133
    Sakurai F, Terada T, Yasuda K, Yamashita F, Takakura Y, Hashida M. 2002. The role of tissue macrophages in the induction of proinflammatory cytokine production following intravenous injection of lipoplexes. Gene Ther 9: 11201126.
  • 134
    Liu F, Shollenberger LM, Huang L. 2004. Non-immunostimulatory nonviral vectors. FASEB J 18: 17791781.
  • 135
    Zhao H, Hemmi H, Akira S, Cheng SH, Scheule RK, Yew NS. 2004. Contribution of Toll-like receptor 9 signaling to the acute inflammatory response to nonviral vectors. Mol Ther 9: 241248.
  • 136
    Sakurai H, Sakurai F, Kawabata K, Sasaki T, Koizumi N, Huang H, Tashiro K, Kurachi S, Nakagawa S, Mizuguchi H. 2007. Comparison of gene expression efficiency and innate immune response induced by Ad vector and lipoplex. J Control Release 117: 430437.
  • 137
    Dow SW, Fradkin LG, Liggitt DH, Willson AP, Heath TD, Potter TA. 1999. Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously. J Immunol 163: 15521561.
  • 138
    Yasuda K, Ogawa Y, Yamane I, Nishikawa M, Takakura Y. 2005. Macrophage activation by a DNA/cationic liposome complex requires endosomal acidification and TLR9-dependent and -independent pathways. J Leukoc Biol 77: 7179.
  • 139
    Hyde SC, Pringle IA, Abdullah S, Lawton AE, Davies LA, Varathalingam A, Nunez-Alonso G, Green AM, Bazzani RP, Sumner-Jones SG, Chan M, Li H, Yew NS, Cheng SH, Boyd AC, Davies JC, Griesenbach U, Porteous DJ, Sheppard DN, Munkonge FM, Alton EW, Gill DR. 2008. CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression. Nat Biotechnol 26: 549551.
  • 140
    Judge AD, Bola G, Lee AC, MacLachlan I. 2006. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol Ther 13: 494505.
  • 141
    Judge A, MacLachlan I. 2008. Overcoming the innate immune response to small interfering RNA. Hum Gene Ther 19: 111124.
  • 142
    Dams ET, Laverman P, Oyen WJ, Storm G, Scherphof GL, van Der Meer JW, Corstens FH, Boerman OC. 2000. Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J Pharmacol Exp Ther 292: 10711079.
  • 143
    Laverman P, Carstens MG, Boerman OC, Dams ET, Oyen WJ, van Rooijen N, Corstens FH, Storm G. 2001. Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection. J Pharmacol Exp Ther 298: 607612.
  • 144
    Semple SC, Harasym TO, Clow KA, Ansell SM, Klimuk SK, Hope MJ. 2005. Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic Acid. J Pharmacol Exp Ther 312: 10201026.
  • 145
    Ishida T, Ichihara M, Wang X, Yamamoto K, Kimura J, Majima E, Kiwada H. 2006. Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. J Control Release 112: 1525.
  • 146
    Ishida T, Wang X, Shimizu T, Nawata K, Kiwada H. 2007. PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. J Control Release 122: 349355.
  • 147
    Wang X, Ishida T, Kiwada H. 2007. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. J Control Release 119: 236244.
  • 148
    Ishida T, Kiwada H. 2008. Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. Int J Pharm 354: 5662.
  • 149
    2009. Gene therapy deserves a fresh chance. Nature 461: 1173.
  • 150
    2009. Mind the spin. Nature 461: 1174.
  • 151
    Baker M. 2010. RNA interference: Homing in on delivery. Nature 464: 12251228.
  • 152
    Levchenko TS, Rammohan R, Lukyanov AN, Whiteman KR, Torchilin VP. 2002. Liposome clearance in mice: The effect of a separate and combined presence of surface charge and polymer coating. Int J Pharm 240: 95102.
  • 153
    Anchordoquy TJ, Armstrong TK, Molina MdC, Allison SD, Zhang Y, Patel MM, Lentz YK, Koe GS. 2004. Formulation considerations for DNA-based therapeutics. In: LuDR, ØieS, editors. Cellular drug delivery: Principle and practice, Totowa, NJ: Humana Press.
  • 154
    de Fougerolles AR. 2008. Delivery vehicles for small interfering RNA in vivo. Hum Gene Ther 19: 125132.
  • 155
    Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M, Elbashir S, Geick A, Hadwiger P, Harborth J, John M, Kesavan V, Lavine G, Pandey RK, Racie T, Rajeev KG, Rohl I, Toudjarska I, Wang G, Wuschko S, Bumcrot D, Koteliansky V, Limmer S, Manoharan M, Vornlocher HP. 2004. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432: 173178.
  • 156
    Rozema DB, Lewis DL, Wakefield DH, Wong SC, Klein JJ, Roesch PL, Bertin SL, Reppen TW, Chu Q, Blokhin AV, Hagstrom JE, Wolff JA. 2007. Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc Natl Acad Sci USA 104: 1298212987.
  • 157
    Meyer M, Dohmen C, Philipp A, Kiener D, Maiwald G, Scheu C, Ogris M, Wagner E. 2009. Synthesis and biological evaluation of a bioresponsive and endosomolytic siRNA-polymer conjugate. Mol Pharm 6: 752762.